Myovant_Logo_FullColor_Cropped.png
Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet
April 12, 2021 06:58 ET | Myovant Sciences, Inc.
SERENE is a Phase 3 single-arm, open-label study evaluating the contraceptive efficacy of investigational relugolix combination tablet in sexually active, healthy women ages 18-35 yearsContraceptive...
Lauren Merendino
Myovant Sciences Appoints Lauren Merendino as Chief Commercial Officer
April 05, 2021 06:58 ET | Myovant Sciences, Inc.
BASEL, Switzerland, April 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of Lauren...
Myovant_Logo_FullColor_Cropped.png
Myovant Sciences Announces European Medicines Agency Validation of Marketing Authorization Application for Relugolix for the Treatment of Advanced Prostate Cancer
March 29, 2021 06:58 ET | Myovant Sciences, Inc.
If approved, relugolix would be the first and only oral androgen deprivation therapy for advanced prostate cancer in EuropeRelugolix is FDA-approved and currently available in the U.S. under the trade...
Myovant_Logo_FullColor_Cropped.png
Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
March 24, 2021 06:30 ET | Myovant Sciences, Inc.
78.4% of women who continued on relugolix combination therapy remained responders (menstrual blood loss < 80 mL) through Week 76 compared with 15.1% of women who discontinued treatment at Week 52...
Myovant_Logo_FullColor_RGB4.png
Myovant Sciences Announces Recipients of “Forward for Health Equity” Grants to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids
March 23, 2021 08:30 ET | Myovant Sciences, Inc.
BASEL, Switzerland, March 23, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the four recipients of...
Myovant_Logo_FullColor_RGB4.png
Myovant Sciences to Present at Upcoming Investor Conferences
February 22, 2021 08:30 ET | Myovant Sciences, Inc.
BASEL, Switzerland, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public...
Myovant_Logo_FullColor_RGB4.png
Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
February 17, 2021 17:02 ET | Myovant Sciences, Inc.; Pfizer Inc.
LIBERTY 1 and LIBERTY 2 achieved 73.4% and 71.2% response rates in menstrual blood loss, with an average reduction of 84.3% from baseline Achieved six of seven key secondary endpoints including...
Myovant_Logo_FullColor_RGB4.png
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
February 17, 2021 08:30 ET | Myovant Sciences, Inc.
BASEL, Switzerland, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity...
Myovant_Logo_FullColor_RGB4.png
HealthyWomen and Myovant Sciences Launch “Voices of Periods” to Fight Menstrual Stigma
February 16, 2021 08:32 ET | Myovant Sciences, Inc.
Six women reflect on their period experiences and journeys to self-advocacy in new video series Video stories and additional information about “Voices of Periods” now available on...
Myovant_Logo_FullColor_RGB4.png
Myovant Sciences Announces Corporate Updates and Financial Results for Third Quarter of Fiscal Year 2020
February 11, 2021 06:55 ET | Myovant Sciences, Inc.
ORGOVYX™ (relugolix) approved by the U.S. Food and Drug Administration (FDA) in December 2020 as the first and only oral GnRH receptor antagonist for adult patients with advanced prostate cancer;...